Total Funding
84
56
Total FundingSeries C raised
Growth Score
-10 pts
Heat Score
-35 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
57368
Kanaph Therapeutics is a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules.
- Jihun Jang: CTO
- Choi Seong-pil: CSO
About the Company
Kanaph Therapeutics is a biotech with activities that range from drug discovery to early-stage clinical trials. It is dedicated to developing next-generation therapeutics for oncology and autoimmune diseases. Their oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the
tumor microenvironment for efficient tumor eradication. The company's autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.
